---
title: "Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286588262.md"
description: "Leerink Partners analyst Roanna Ruiz has maintained a Buy rating on Ibio (IBIO) with a price target of $6.00. Ruiz, a 2-star analyst, has an average return of 0.6% and a 46.18% success rate. The analyst consensus for Ibio is Strong Buy, with a price target consensus of $5.80."
datetime: "2026-05-15T15:28:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286588262.md)
  - [en](https://longbridge.com/en/news/286588262.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286588262.md)
generator: "portal-rs"
---

# Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)

In a report released today, Roanna Ruiz from Leerink Partners maintained a Buy rating on Ibio, with a price target of $6.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Ruiz is a 2-star analyst with an average return of 0.6% and a 46.18% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Ibio, Cormedix, and Aquestive Therapeutics.

Ibio has an analyst consensus of Strong Buy, with a price target consensus of $5.80.

### Related Stocks

- [IBIO.US](https://longbridge.com/en/quote/IBIO.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [CRMD.US](https://longbridge.com/en/quote/CRMD.US.md)
- [AQST.US](https://longbridge.com/en/quote/AQST.US.md)

## Related News & Research

- [iBio FY26 net loss widens to $33.04 million; revenue drops to $100,000](https://longbridge.com/en/news/297313027.md)
- [iBio advances IBIO-600 into Phase 1 multiple-ascending-dose trial stage after completing single-ascending-dose dosing](https://longbridge.com/en/news/297325770.md)
- [FDA grants priority review to Genentech’s Enspryng for MOGAD](https://longbridge.com/en/news/298539804.md)
- [09:28 ETNew LabCentral Program "The Loop" Offers International Biotech Start-Ups and Partner Organizations Curated Learnings Directly from U.S. Market](https://longbridge.com/en/news/298328140.md)
- [iBio CEO joins Wells Fargo Annual Healthcare Conference fireside chat](https://longbridge.com/en/news/297695352.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**